Vor Bio Presents Data Update On Trem-cel At HSCT Conference; Primary Neutrophil Engraftment Of Trem-cel Achieved In All Seven Patients Treated To Date
Portfolio Pulse from Benzinga Newsdesk
Vor Bio (NASDAQ:VOR) has presented updated clinical data from its Phase 1/2a study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). The data shows successful engraftment of trem-cel in all seven patients treated to date. The company also reported hematologic protection in three patients treated with multiple cycles of Mylotarg. Vor Bio's next steps include dose escalation of Mylotarg and providing treatment opportunities for trem-cel patients who become measurable residual disease positive or relapse.

November 09, 2023 | 9:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vor Bio's updated clinical data shows promising results for its trem-cel treatment in AML patients. This could potentially boost investor confidence in the company's approach and its future prospects.
The successful engraftment of trem-cel in all seven patients and the observed hematologic protection in patients treated with Mylotarg are positive outcomes for Vor Bio. This could potentially lead to increased investor confidence in the company's approach and its future prospects, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100